Gary M. Phillips, M.D. has served as OrphoMed’s President & Chief Executive Officer since April 2018. Dr. Phillips has nearly three decades of experience in the pharmaceutical and healthcare industries, leading strategy, business/corporate development, and commercial operations functions. Before joining OrphoMed, Dr. Phillips served as Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals since 2013. Previously, he was Head of Global Health & Healthcare Industries at the World Economic Forum. Earlier, he served as President of Reckitt Benckiser Pharmaceuticals North America (now Indivior), and he held dual roles as President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb. Additionally, he has served in executive roles at Merck Serono, Novartis, and Wyeth. From the University of Pennsylvania, he earned a B.A. in Biochemistry with summa cum laude and Phi Beta Kappa distinctions from the College of Arts and Sciences, an MBA from the Wharton School, and an M.D. with Alpha Omega Alpha distinction from the School of Medicine. Dr. Phillips maintains an active medical license and practiced as a general medicine clinician/officer in the U.S. Navy, from which he was honorably discharged as lieutenant commander. He currently serves on the boards of directors of Aldeyra Therapeutics and Rheon Medical SA and previously on the boards of Zyla Life Sciences, Inotek Pharmaceuticals and Envisia Therapeutics.